Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATX-01 in Myotonic Dystrophy Type 1
NCT06300307Phase 2Recruiting
- Sponsor
- ARTHEx Biotech
- Start
- Oct 2024
- Primary completion
- Jul 2027
- Modality
- Gene Editing, Gene Silencing, Modified DNA Oligonucleotides
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in myotonic dystrophy type 1 (DM1) comparing ATX-01 Arm with Placebo Arm (2 arms). Primary endpoint: Incidence of adverse events at 120 days. Started Oct 2024; status: recruiting.
02
Drugs
ATX-01
03
Conditions
myotonic dystrophy type 1 (DM1)
Beyond the preview
Go deeper on NCT06300307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06300307.